Access to Unapproved Drugs: FDA Policies on Compassionate Use and Emergency Use Authorization EveryCRSReport.com FDA moves toward easing restrictions on certain peptides BioPharma Dive FDA Unapproved Drugs: The $7.5 Billion 505(b)(2) Opportunity Most Pharma Execs Are Ignoring DrugPatentWatch Transform Data into Market Domination The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York